Tag: Drug Discovery Award

Antra Chaudhary | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Antra Chaudhary,
Jamia Hamdard University, New Delhi, India.

Antra Chaudhary
Affiliation Jamia Hamdard University
Country India
Scopus ID 57406830100
Documents 10
Citations 119
h-index 5
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event World Science Awards
ORCID 0009-0006-9003-5566

Antra Chaudhary is an Indian pharmacology researcher and doctoral scholar recognized for her contributions to bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection research. Her academic work has focused extensively on translational pharmacological approaches involving medicinal plants, osteoporosis therapeutics, neuroinflammation, stem cell-based therapies, and molecular signaling pathways associated with disease progression and tissue protection.[1] She is currently pursuing doctoral research at Jamia Hamdard University under the supervision of Prof. Divya Vohora, where her investigations explore the therapeutic potential of natural compounds against glucocorticoid-induced bone damage and postmenopausal osteoporosis.[2]

Abstract

This academic article presents a scholarly overview of the research contributions, scientific achievements, and professional development of Antra Chaudhary, a pharmacology researcher specializing in bone pharmacology, oxidative stress, inflammatory disorders, and neuroprotection. Her research has contributed to understanding molecular signaling pathways associated with osteoporosis, ischemic stroke, rheumatoid arthritis, and mitochondrial dysfunction. Through interdisciplinary pharmacological investigations involving in vitro and in vivo models, her work has emphasized translational therapeutic strategies and the use of bioactive compounds for disease modulation.[3] The article further documents her academic qualifications, awards, technical expertise, scientific publications, and suitability for academic recognition in the field of pharmacology and biomedical sciences.

Keywords

Bone Pharmacology, Oxidative Stress, Osteoporosis, Pharmacology, Neuroprotection, Medicinal Plants, Inflammatory Diseases, Stem Cell Therapy, Molecular Pharmacology, Translational Research, Rheumatoid Arthritis, Glucocorticoid-Induced Bone Damage, Pharmacodynamics, Biomedical Sciences.

Introduction

Contemporary pharmacological research increasingly emphasizes translational approaches that integrate molecular biology, therapeutic intervention, and clinical applicability. Researchers in pharmacology are actively investigating novel compounds and signaling pathways to address chronic diseases, neurodegeneration, inflammatory disorders, and metabolic dysfunctions.[4] Within this scientific landscape, Antra Chaudhary has contributed to emerging research areas involving osteoporosis therapeutics, oxidative stress modulation, neuroinflammation, and medicinal plant-based pharmacological interventions.

Her academic journey reflects a progression through pharmaceutical sciences and toxicology training, supported by competitive national examinations including GPAT and NIPER-JEE. She has participated in multidisciplinary research projects and advanced laboratory investigations utilizing molecular, histological, and imaging-based techniques for experimental pharmacology studies.[5]

Research Profile

Antra Chaudhary completed her Master of Science in Pharmacology and Toxicology from the National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, where she worked on medicinal plant extracts from North-East India for inflammatory disease research. Her doctoral research at Jamia Hamdard University focuses on bone pharmacology and oxidative stress biology under the supervision of Prof. Divya Vohora.[2]

Her technical expertise encompasses a broad range of experimental methodologies, including Western blotting, RT-PCR, immunohistochemistry, fluorescence microscopy, micro-computed tomography, small animal imaging, and cell culture systems. She has also demonstrated competence in pharmacological data analysis using GraphPad Prism and image analysis software.[3]

  • DST WISE KIRAN Fellow for doctoral research in Life Sciences.
  • Qualified GPAT and NIPER-JEE examinations with competitive national rankings.
  • Recipient of the Young Investigator Award 2025 at IPC-IPSCON 2025.
  • Contributor to peer-reviewed journals in pharmacology and neuroscience.

Research Contributions

The scientific contributions of Antra Chaudhary span multiple pharmacological domains, including neuroprotection, osteoporosis, inflammatory signaling, and mitochondrial biology. Her collaborative studies have investigated the role of cardiolipin-mediated mitochondrial protection in ischemic stroke and the therapeutic implications of stem cell-mediated inflammasome modulation.[1]

Her work on bone-targeted daidzein-loaded hydroxyapatite nanoparticles evaluated osteogenic potential and pharmacodynamic activity in postmenopausal osteoporosis models, highlighting nanotechnology-assisted therapeutic delivery systems.[8] Additionally, she contributed to research exploring TLR4/NF-κB and Keap1/Nrf2 signaling pathways in rheumatoid arthritis using perillyl alcohol interventions.[2]

Her review publications further discuss CRISPR/Cas9 technologies in neurological disorders, drug repurposing strategies for stroke intervention, and glial cell responses in neurodegenerative conditions.[5]

Publications

Selected Research Articles

  1. Gautam N, Sharma P, Chaudhary A, et al. Investigating the osteogenic potential of bone-targeted daidzein loaded hydroxyapatite nanoparticles for postmenopausal osteoporosis. Journal of Drug Targeting, 2025.
  2. Sarmah D, Sarkar A, Datta A, et al. Cardiolipin-mediated alleviation of mitochondrial dysfunction is a neuroprotective effect of statin in ischemic stroke. ACS Chemical Neuroscience, 2023.
  3. Puppala ER, Jain S, Saha P, et al. Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways. Phytomedicine, 2022.

Review Articles

  • Advancement in CRISPR/Cas9 technology to better understand and treat neurological disorders.
  • Drug repurposing for stroke intervention.
  • Glial cells response in stroke.

Research Impact

The research contributions of Antra Chaudhary demonstrate interdisciplinary relevance across pharmacology, neuroscience, and biomedical sciences. Her publications address clinically significant challenges associated with osteoporosis, ischemic stroke, inflammatory diseases, and oxidative stress-mediated tissue injury.[11]

Her collaborative work in molecular pharmacology and translational therapeutics contributes to ongoing scientific efforts aimed at developing safer and more effective treatment strategies. The integration of medicinal plant research, nanotechnology-based drug delivery systems, and cellular signaling investigations highlights the translational significance of her scientific profile.[2]

Award Suitability

Antra Chaudhary’s academic profile reflects sustained engagement in experimental pharmacology, translational biomedical research, and scientific dissemination through peer-reviewed publications and conference presentations. Her recognition through the Young Investigator Award at IPC-IPSCON 2025 further demonstrates professional acknowledgment of her contributions within the pharmacological research community.[3]

Her expertise in advanced laboratory techniques, coupled with her publication record and participation in international scientific activities, supports her suitability for academic recognition in the field of pharmacology and bone research. The interdisciplinary scope of her work aligns with contemporary priorities in therapeutic innovation and disease prevention.

Conclusion

Antra Chaudhary represents an emerging researcher in pharmacology whose scientific activities encompass bone pharmacology, oxidative stress biology, neuroprotection, and translational therapeutics. Through experimental research, scholarly publications, and active participation in scientific conferences, she has contributed to advancing knowledge in multiple biomedical domains. Her work continues to support the development of innovative therapeutic approaches aimed at improving disease management and bone health outcomes.[1]

References

  1. Jamia Hamdard University. (2026). Doctoral Research Profile of Antra Chaudhary.
  2. Jamia Hamdard University. (2026). Bone Pharmacology and Oxidative Stress Research Program.
  3. Elsevier. (2025). Pharmacological approaches in osteoporosis and translational therapeutics.
  4. Drug Discovery Today. (2022). Drug repurposing for stroke intervention.
    https://doi.org/10.1016/j.drudis.2022.03.014
  5. National Institute of Pharmaceutical Education and Research. (2020). MS Research Project Documentation.

Mohmmad Younus Wani | Medicinal Chemistry | Excellence in Research Award

Published on by World Science Awards

Assoc. Prof. Dr. Mohmmad Younus Wani | Medicinal Chemistry | Excellence in Research Award

University of Jeddah, Saudi Arabia

Assoc. Prof. Dr. Mohmmad Younus Wani is an accomplished Associate Professor at the University of Jeddah, specializing in medicinal and organic chemistry with a strong focus on drug discovery and antimicrobial resistance. His research centers on the development of small molecule inhibitors and innovative therapeutic strategies to combat drug-resistant pathogens and hospital-acquired infections. With over 90 high-impact publications, an h-index of 33, and more than 4,100 citations, he has established a significant global research presence. Dr. Wani has secured multiple competitive research grants, including major funded projects as Principal Investigator, and holds several US patents in antifungal therapeutics. He has extensive international research experience, having worked in the United States, Portugal, and India, and actively collaborates across multidisciplinary teams. His work contributes to advancing healthcare solutions and addressing critical global challenges in infectious diseases and antimicrobial resistance.

Citation Metrics (Scopus)

3500
2500
1500
500

Citations
3,152

h-index
29

Documents
92

Citations

h-index

Documents

Featured Publications

MA Malik, MY Wani, MA Hashim (2012).
Microemulsion method: A novel route to synthesize organic and inorganic nanomaterials: 1st Nano Update
Arabian Journal of Chemistry | Journal Article · 2012 · 📊 Citations: 864

MA Malik, OA Dar, P Gull, MY Wani, AA Hashmi (2018).
Heterocyclic Schiff base transition metal complexes in antimicrobial and anticancer chemotherapy
MedChemComm | Journal Article · 2018 · 📊 Citations: 459

S Kumar, MY Wani, CT Arranja, JA e Silva, B Avula, AJFN Sobral (2015).
Porphyrins as nanoreactors in the carbon dioxide capture and conversion: a review
Journal of Materials Chemistry A | Journal Article · 2015 · 📊 Citations: 161

MA Malik, MY Wani, SA Al-Thabaiti, RA Shiekh (2014).
Tetrazoles as carboxylic acid isosteres: chemistry and biology
Journal of Inclusion Phenomena and Macrocyclic Chemistry | Journal Article · 2014 · 📊 Citations: 161

MY Wani, MA Hashim, F Nabi, MA Malik (2011).
Nanotoxicity: dimensional and morphological concerns
Advances in Physical Chemistry | Journal Article · 2011 · 📊 Citations: 136

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Jiunn-Liang Ko | Pharmaceutical Science | Research Excellence Award

Chung Shan Medical University | Taiwan

Dr. Jiunn-Liang Ko is a distinguished scholar in the fields of biochemistry, toxicology, and medical sciences, with a research career spanning more than three decades. He earned his Ph.D. in Biochemistry from the College of Medicine at National Taiwan University (1995), following a Master’s and Bachelor’s degree in Biology from Fu-Jen University. His academic and scientific journey reflects unwavering dedication to advancing biomedical research, particularly in molecular toxicology, environmental health, and translational medicine. Dr. Ko began his professional research career as a Postdoctoral Fellow at the Taiwan Agricultural Chemicals and Toxic Substances Research Institute, where he contributed to pioneering work in biopesticide safety and toxicological mechanisms. In 2003, he joined Chung-Shan Medical University, where he progressed from Professor in the Institute of Toxicology to Director of multiple strategic units, including the Research & Development Office, the Instrumental Center, and the Institute of Medical and Molecular Toxicology. His leadership has been instrumental in enhancing interdisciplinary research capacity, laboratory infrastructure, and academic excellence at the institution. Since 2011, Dr. Ko has served as Professor at the Institute of Medicine at Chung-Shan Medical University, continuing to lead high-impact research, mentor scholars, and foster international collaborations. His work encompasses molecular carcinogenesis, toxicogenomics, and the cellular responses to environmental hazards, positioning him as a key contributor to advancing understanding of public health risks and disease prevention. Over his career, he has authored numerous peer-reviewed publications, contributed to national and international projects, and collaborated across academia, healthcare, and applied science sectors. His research outputs are recognized for their scientific rigor and real-world relevance, influencing policy, clinical practice, and biosafety standards. Through his sustained academic leadership, scientific innovation, and commitment to education, Dr. Jiunn-Liang Ko continues to contribute significantly to global biomedical research and the advancement of public health.

Profiles: Scopus | ORCID | Google Scholar

Featured Publications

Yang, Y.-T., Hsu, C.-H., Wang, Y.-F., Chang, Y.-J., Yang, H.-J., Ko, J.-L., & Yang, K.-C. (2022). Worsening quality of life in young adult, highly educated, and married female patients with vitiligo: A hospital-based case control study in Taiwan. International Journal of Environmental Research and Public Health, 19(11), 6741.

Chang, J.-C., Chiou, J.-Y., Ko, J.-L., Huang, J.-Y., & Lue, K.-H. (2021). Early bronchiolitis contributes to preschool asthma. Children, 8(12), 1176.

Hsin, I.-L., Shen, H.-P., Chang, H.-Y., Ko, J.-L., & Wang, P.-H. (2021). Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 positive feedback loop induces cell cycle arrest by dual PI3K/mTOR inhibitor PQR309 in endometrial cancer cell lines. Cells, 10(11), 2916.

Hsiao, Y.-P., Chen, H.-L., Tsai, J.-N., Lin, M.-Y., Liao, J.-W., Wei, M.-S., Ko, J.-L., & Ou, C.-C. (2021). Administration of Lactobacillus reuteri combined with Clostridium butyricum attenuates cisplatin-induced renal damage by gut microbiota reconstitution, increasing butyric acid production, and suppressing renal inflammation. Nutrients, 13(8), 2792.

Wu, S.-W., Ko, J.-L., Liu, B.-H., & Yu, F.-Y. (2020). A sensitive two-analyte immunochromatographic strip for simultaneously detecting aflatoxin M1 and chloramphenicol in milk. Toxins, 12(10), 637.

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by World Science Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Ashish Patel | Pharmaceutical Chemistry | Best Researcher Award

Published on by World Science Awards

Assoc. Prof. Dr. Ashish Patel | Pharmaceutical Chemistry | Best Researcher Award

Parul Institute of Pharmacy, Parul University, India

Dr. Ashish Patel is an Associate Professor at Parul Institute of Pharmacy, Parul University, Vadodara, Gujarat, with extensive expertise in Pharmaceutical Chemistry. He earned his M.Pharm degree from M.S. University of Baroda in 2010 and subsequently completed his Ph.D. at R.K. University in 2016, focusing on the design and development of bioactive compounds. Over the course of his academic career, Dr. Patel has guided more than 25 postgraduate students and 5 Ph.D. scholars, demonstrating his commitment to mentorship and fostering research excellence. His professional experience includes curriculum development, laboratory management, and active participation in national and international conferences, contributing to the academic community both as a researcher and educator. Dr. Patel’s research interests are broad and interdisciplinary, encompassing drug design, green synthesis, anti-cancer and anti-diabetic compounds, and computational chemistry, with particular emphasis on virtual screening and structure-activity relationship studies. His research skills include microwave-assisted synthesis, FT-IR spectroscopy, molecular docking, and computer-aided drug design, enabling him to bridge theoretical approaches with experimental validation. To date, he has published 83 research articles, accumulated 574 citations, and maintains an h-index of 15, reflecting the impact of his contributions to pharmaceutical sciences. Dr. Patel has been recognized for his excellence in teaching and research through multiple awards, including the Leadership Award in the Professor’s Training Program at Parul University, highlighting his dedication to professional development and leadership in academia. In conclusion, Dr. Ashish Patel exemplifies the integration of teaching, mentorship, and innovative research in pharmaceutical chemistry. His career reflects a sustained commitment to advancing scientific knowledge, nurturing future researchers, and contributing to the global understanding of drug discovery and development, establishing him as a distinguished figure in his field.

Profile: Scopus | ORCID | Google Scholar | Staff Page

Featured Publications

  1. Patel, A., Rajendran, M., Shah, A., Patel, H., Pakala, S. B., & Karyala, P. (2021). Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV. Journal of Biomolecular Structure and Dynamics, 1–9.

  2. Saralaya, M. G., Patel, P., Patel, A., Manish, Roy, & Samresh, Patel. (2010). Antidiarrheal activity of methanolic extract of Moringa oleifera Lam roots in experimental animal models. International Journal of Pharmaceutical Research, 2(2), 25–29.

  3. Patel, A., Patel, S., Mehta, M., Patel, Y., Patel, R., Shah, D., Patel, D., & Shah, U. (2022). A review on synthetic investigation for quinoline—Recent green approaches. Green Chemistry Letters and Reviews, 15(2), 337–372.

  4. Patel, A. D., Pasha, T. Y., Lunagariya, P., Shah, U., Bhambharoliya, T., … [additional authors]. (2020). A library of thiazolidin‐4‐one derivatives as protein tyrosine phosphatase 1B (PTP1B) inhibitors: An attempt to discover novel antidiabetic agents. ChemMedChem, 15(13), 1229–1242.

  5. Patel, P., Shah, D., Bambharoliya, T., Patel, V., Patel, M., Patel, D., Bhavsar, V., … [additional authors]. (2024). A review on the development of novel heterocycles as α-glucosidase inhibitors for the treatment of type-2 diabetes mellitus. Medicinal Chemistry, 20(5), 503–536.

Yves Patrick Ango | Chimie Pharmaceutique | Best Researcher Award

Published on by World Science Awards

Dr. Yves Patrick Ango | Chimie Pharmaceutique | Best Researcher Award

Faculty of Medicine and Biomedicals Sciences, the University of Yaoundé 1, Cameroon

Dr. Yves Patrick Ango is a distinguished Cameroonian researcher and Senior Lecturer at the Department of Pharmacotoxicology, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, specializing in Natural Product Chemistry with a focus on isolating, characterizing, and testing bioactive compounds for anticancer and antimicrobial applications. He earned his Bachelor’s degree in Chemistry, followed by a Master’s and D.E.A. in Organic Chemistry at the University of Yaoundé I, and successfully completed his Doctorat/Ph.D. in Natural Product Chemistry with “Très Honorable” distinction. Throughout his career, Dr. Ango has combined academic excellence with international exposure, undertaking multiple research fellowships at the University of Botswana supported by IPICS, OPCW, DAAD, TWAS, and Humboldt networks, which enriched his expertise and fostered global collaborations in phytochemistry and pharmacology. His research portfolio includes 13 peer-reviewed publications in reputed journals such as Cancer Reports, Natural Product Research, Phytochemistry Letters, and Helvetica Chimica Acta, earning 202 citations and an h-index of 7, reflecting the impact of his scholarly contributions. His primary research interests revolve around discovering natural molecules with therapeutic potential, linking African traditional medicine to modern drug discovery, and addressing global health challenges such as cancer and drug resistance. Dr. Ango possesses strong research skills in natural product isolation, structural elucidation, biological activity testing, and collaborative scientific networking, alongside mentoring students and advancing pharmacotoxicology education in Cameroon. He has actively contributed to scientific development by participating in high-level international workshops and symposia, building knowledge-sharing platforms across Africa and Europe. His academic achievements and dedication to excellence have been recognized through prestigious international sponsorships and grants that reflect his research quality and leadership potential. With his passion for science, proven track record, and collaborative spirit, Dr. Yves Patrick Ango stands as a promising researcher whose contributions to natural product chemistry and biomedical innovation will continue to make a meaningful impact on global health research and capacity building.

Profile: Scopus | ORCID

Featured Publications

Akamse, M. A., Kamgo, V. D., Ango, P. Y.*, Djuidje Fotsing, M. C., Fomat, B. H. P., Mmutlane, E., Fotso, G. W., Kapche, D. W. F. G., Zingué, S., & Ndinteh, D. T. (2025). Arjunolic acid from Terminalia ivorensis A. Chev (Combretaceae) possesses anti-breast cancer effects in vitro and in vivo. Cancer Reports, 8(1), e70337, 1–14.

Choungo, V. N., Ango, P. Y.*, Nzepang, A., Fotso, G. W.**, Lenta, B. N., Sewald, N., & Kapche, D. W. F. G. (2025). Combretumlignan, a new cyclolignan and other constituents from Combretum zenkeri (Combretaceae). Heliyon.

Ango, P. Y.*, Kenembeni, M. K., Mapitse, R., Fotso, G. W., Garba, J. K., Mbazoa, C. D., Ndinteh, D. T., Kapche, D. W. F. G.**, & Wandji, J. (2025). The isolation, characterization and activity testing of two previously undescribed flavonoid glycosides and other constituents from the stem bark of Olax latifolia (Olacaceae). Natural Product Research.

Ango, P. Y.*, Ghoda, A. W., Abega, D. F., Mapitse, R., Kuete, V., Ngadjui, B. T., Fotso, G. W., & Kapche, D. W. F. G. (2024). Aframomumlabdane, a new bislabdane diterpenoid from Aframomum arundinaceum (Zingiberaceae). Natural Product Research.

Mogue, L. D. K., Ango, P. Y., Fotso, G. W., Mapitse, R., Kuete, V., Demirtas, I., Samuel, Y., & Ngadjui, B. T. (2019). Two new polyhydroxylated pentacyclic triterpenes with cytotoxic activities from Manilkara pelligriniana (Sapotaceae). Phytochemistry Letters, 31, 161–165.

Liang Zhou | Clinical Pharmacology | Best Researcher Award

Published on by World Science Awards

Ms. Liang Zhou | Clinical Pharmacology | Best Researcher Award

Shanghai Henlius Biotech Inc., China

Ms. Liang Zhou is a distinguished clinical pharmacology professional with extensive experience in oncology drug development, pharmacokinetics, and translational research. She earned her Master’s degree in Drug Metabolism and Pharmacokinetics from the China Pharmaceutical University in 2008, which laid the foundation for her successful career in pharmaceutical sciences. Over the years, she has held progressive positions in leading global and Chinese organizations, including Associate Senior Scientist at Wuxi Apptec, Demo Chemist at Thermo Fisher Shanghai, Associate Director of Clinical Pharmacology at Mosim, and currently serves as the Senior Director of Clinical Pharmacology at Shanghai Henlius Biotech, Inc. since 2021. In these roles, she has contributed to more than 11 significant clinical trial programs across China, Australia, Japan, Europe, and the United States, with a strong focus on first-in-human (FIH) trials, PK/PD analysis, and oncology indications such as breast cancer, lymphoma, AML, NSCLC, gastric and pancreatic cancers, among others. Her research interests center on oncology drug development, dose exploration studies, biomarker integration, and regulatory science to accelerate access to novel therapies. With 23 academic documents, 91 citations, and an h-index of 4, Ms. Zhou demonstrates measurable scholarly impact, supported by her memberships in professional societies such as the Chinese Society of Clinical Oncology (CSCO). She has also enhanced her expertise through specialized training in GCP compliance, oncology drug development, and advanced pharmacometrics including R-language applications. Her skills encompass pharmacokinetic modeling, clinical trial design, regulatory submission, and team leadership, which collectively position her as a key figure in clinical pharmacology. Recognized for her contributions to cancer research and drug development, she continues to build a strong professional profile with the potential for international recognition. In conclusion, Ms. Liang Zhou’s blend of academic excellence, clinical research leadership, and commitment to advancing oncology therapeutics makes her a deserving candidate for prestigious awards and a driving force in global biomedical innovation.

Profile: Scopus

Featured Publications

Li, X., Zhang, Y., Wang, J., Chen, H., Zhou, L., Liu, M., … [et al.]. (2023). HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: An open-label, dose-escalation, phase 1 trial.(5)

Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Published on by World Science Awards

Dr. Asif Khaliq | Pharmaceutical Sciences | Best Researcher Award

Dr. Asif Khaliq is a distinguished clinical pharmacist and public health researcher with extensive experience across Pakistan and Australia. With over 15 years of cumulative expertise in pharmacy practice, healthcare management, and academic research, he has played pivotal roles in both hospital settings and global health research initiatives. Dr. Khaliq currently serves as a Clinical Pharmacist at Atherton Hospital, Queensland Health, where he contributes to medication reconciliation, patient consultation, and therapeutic drug monitoring. His broad qualifications in pharmacy, public health, and health management uniquely position him at the intersection of clinical service and evidence-based research. Notably, he has authored around 30 peer-reviewed journal articles and has presented his work at several international conferences. His commitment to improving patient care is reflected in his involvement in projects on antimicrobial stewardship, immunization safety, medication cost optimization, and community health surveillance. A registered pharmacist in both Australia and Pakistan, Dr. Khaliq continues to expand his professional credentials through ongoing training and professional development. His multidisciplinary knowledge and dedication to collaborative, data-driven healthcare improvement make him a leading candidate for honors in research and clinical excellence.

Professional Profile

Education

Dr. Asif Khaliq possesses a diverse and robust academic background that integrates pharmacy, health management, and public health. He earned his Doctor of Pharmacy (PharmD) from the University of Karachi in 2009, laying a solid foundation in pharmaceutical sciences. He later pursued an MBA in Health Management from the Institute of Business Management (IoBM), Karachi, in 2014, equipping him with managerial and strategic skills essential for healthcare administration. In 2017, he obtained a Master of Public Health (MPH) from Baqai Medical University, further expanding his expertise into population health, disease prevention, and health systems. Most recently, he completed a Ph.D. in Public Health at Queensland University of Technology (QUT), Australia, in 2023. His doctoral research focused on critical issues in public health, integrating practical clinical knowledge with research methodologies. In addition to these core degrees, Dr. Khaliq has cleared the Knowledge Assessment of Pharmaceutical Sciences (KAPS) by the Australian Pharmacy Council and has demonstrated English language proficiency through PTE Academic. His academic trajectory reflects a commitment to lifelong learning and interdisciplinary mastery, qualifying him to address complex healthcare challenges at both clinical and systemic levels.

Professional Experience

Dr. Khaliq’s professional journey spans multiple sectors, including hospital pharmacy, public health research, and academic instruction. Currently, he serves as a Clinical Pharmacist at Atherton Hospital under Queensland Health, where he provides vital services including medication review, drug interaction management, therapeutic optimization, and discharge planning. His responsibilities also involve daily clinical monitoring and interdisciplinary collaboration with physicians and nursing staff. Previously, he held pharmacist roles at Infinity Pharmacy Earlville Upper, Allora Pharmacy, and Boulder Pharmacy across Queensland, Australia. In these roles, he handled immunization services, controlled substance management, MedsChecks, and patient counseling. Notably, Dr. Khaliq served as a Research Coordinator at Aga Khan University Hospital, Pakistan, where he supervised international clinical trials and led efforts in typhoid outbreak investigations. He also worked in various pharmacist roles at Aga Khan University Hospital’s emergency and pediatrics departments, gaining critical experience in medication reconciliation, IV-to-oral drug conversions, and poison management. His early career included logistics and inventory roles with Médecins Sans Frontières, further enriching his understanding of pharmaceutical supply chains. This comprehensive experience makes Dr. Khaliq uniquely capable of blending clinical insights with research acumen and operational excellence.

Research Interests

Dr. Asif Khaliq’s research interests lie at the nexus of clinical pharmacy, public health, and healthcare systems management. He is particularly focused on areas such as antimicrobial stewardship, vaccine safety and immunogenicity, medication adherence, and cost-effective therapeutic strategies. During his Ph.D. studies at Queensland University of Technology, he explored healthcare outcomes linked to pharmacological practices and population-level health interventions. His work frequently integrates health surveillance, epidemiology, and evidence-based medicine to address real-world challenges in both hospital and community settings. He has led or contributed to major research projects including randomized controlled trials on antibiotic use in pediatric diarrhea and typhoid outbreak control. In recent roles, he has also investigated adverse events following immunization (AEFI), resistance patterns in Salmonella species, and systematic reviews on outbreak trends in developing regions. Dr. Khaliq is deeply committed to identifying research gaps in healthcare delivery and prescribing patterns, aiming to improve policy, patient outcomes, and clinical protocols. His interdisciplinary research interests reflect his training in pharmacy, health management, and public health, empowering him to make meaningful contributions to both academic literature and healthcare practice.

Research Skills

Dr. Khaliq possesses a broad and advanced set of research skills that enhance his ability to contribute to multidisciplinary studies and clinical investigations. He is highly proficient in clinical trial management, including participant recruitment, data collection, and adverse event reporting. His expertise extends to secondary data analysis, especially in reviewing hospital records, surveillance data, and immunization outcomes. He is experienced in systematic reviews and meta-analyses, utilizing medical databases and analytical frameworks to synthesize health evidence. Dr. Khaliq also brings strong capabilities in pharmacovigilance, therapeutic drug monitoring, and drug utilization evaluations. In the realm of academic publishing, he has served as a guest editor and peer reviewer, contributing to journal special issues and maintaining scientific rigor. He is adept at grant proposal development, contributing to multiple research applications during his tenure at academic and healthcare institutions. Moreover, his familiarity with health informatics tools—such as Micromedex, MedAdvisor, and clinical guidelines—enables him to integrate real-time data with clinical decision-making. His research skills are complemented by his teaching experience and mentorship, allowing him to train future researchers and practitioners in evidence-based methods.

Awards and Honors

Dr. Asif Khaliq has garnered recognition for his dedication to public health research and pharmaceutical practice through various academic and professional achievements. He was a selected speaker at notable international forums such as the IMPACT MAKER 2020 conference in Brisbane, where he presented novel research on coexisting forms of malnutrition. His earlier work on poisoning case management was also showcased at the 4th FMIC Conference in Kabul. At the 11th International Coalition Against Typhoid Conference in Hanoi, Vietnam, Dr. Khaliq presented two critical posters on typhoid drug resistance and outbreak investigation, underscoring his commitment to infectious disease research. He has published approximately 30 peer-reviewed papers, several of which have appeared in reputable international journals. While formal individual awards may not be listed, his multiple research leadership roles, international conference engagements, and responsibilities as a guest editor reflect his strong reputation in both academic and healthcare sectors. His continuous pursuit of professional certifications, including immunization and UTI management, also highlights a dedication to clinical excellence. These accomplishments collectively underscore his potential as an award-worthy contributor to global health and pharmacy practice.

Conclusion

In conclusion, Dr. Asif Khaliq exemplifies the ideal profile of a clinical researcher who bridges academic insight with frontline healthcare delivery. His academic credentials across pharmacy, health management, and public health are complemented by his extensive experience in clinical pharmacy settings in both Pakistan and Australia. Through his research on antibiotic use, immunization safety, and medication optimization, Dr. Khaliq addresses key healthcare challenges relevant to global and regional populations. He demonstrates not only technical knowledge but also leadership in research coordination, interdisciplinary collaboration, and scientific communication. His professional ethos is defined by evidence-based practice, patient-centered care, and continual improvement. As a registered pharmacist in two countries and an active participant in international academic dialogues, Dr. Khaliq is well-positioned to further influence policy, education, and clinical standards. His consistent pursuit of professional development, publication, and mentorship reflects a commitment to excellence that aligns with the objectives of the Best Researcher Award. Recognizing his contributions would not only honor individual achievement but also highlight the critical role of pharmacist-researchers in shaping modern healthcare systems.

Publications Top Notes

1. Mission of Polio Eradication in Pakistan – A Review on Challenges and Future Recommendations

  • Year: 2025

  • Source: New Microbes and New Infections (Open Access)

2. Adherence to Complementary Feeding Indicators and Their Associations with Coexisting Forms of Malnutrition in Children Aged Between 6 to 23.9 Months of Age

  • Year: 2023

  • Source: Journal of Public Health

 

Yulin Mo | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Yulin Mo | Pharmaceutical Science | Best Researcher Award

Shanghai University, China

Mo Yulin is an accomplished researcher and medical professional specializing in pharmacology and traditional Chinese medicine. Born in 1986 in Hezhou, Guangxi, China, he currently serves as a physician at Nanning Hospital of Traditional Chinese Medicine. With over a decade of clinical and research experience, Mo combines medical practice with scientific inquiry, focusing on the mechanistic basis of bone diseases such as glucocorticoid-induced osteoporosis (GIO). He obtained his Master of Medical Science degree in Pharmacology from Guangdong Medical University, where he cultivated a strong foundation in experimental pharmacology, molecular techniques, and data analysis. His academic journey began at Youjiang Medical University for Nationalities, where he earned his Bachelor’s degree in Clinical Medicine. Mo Yulin has actively contributed to several nationally funded research projects and has co-authored high-impact journal articles. His work focuses on the intersection of Traditional Chinese Medicine and modern pharmacological research, particularly targeting bone-related diseases. With a sound understanding of laboratory protocols, animal models, and statistical software, he continues to contribute to both clinical and academic advancements. Mo’s research is well-recognized in peer-reviewed journals and by national scientific foundations, reinforcing his potential as a leading figure in integrative medical research.

Professional Profile

Education

Mo Yulin’s educational background is rooted in a solid blend of clinical and pharmacological sciences. He began his academic journey at Zhaoping County Middle School, completing his secondary education in 2004. He then enrolled at Youjiang Medical University for Nationalities in September 2005, where he pursued a Bachelor’s degree in Clinical Medicine and graduated in June 2010. His interest in the theoretical underpinnings of medicine and drug mechanisms led him to pursue postgraduate studies in Pharmacology. In September 2016, he was admitted to Guangdong Medical University, a recognized institution in medical sciences, where he undertook a full-time Master’s program in Medical Science with a concentration in pharmacology. He completed this program in June 2019. His master’s thesis, titled “Exploring the pathogenesis of GIO and the intervention effect of Danshensu based on TXNIP mediated mitochondrial oxidative phosphorylation,” demonstrated a deep integration of molecular biology, pharmacology, and traditional Chinese medicine. His academic record is also supplemented by participation in various specialized training programs and international summer courses, including workshops on stem cell biology and network pharmacology. This extensive and interdisciplinary academic training has equipped him with a broad understanding of clinical medicine, experimental design, and the pharmacological sciences.

Professional Experience

Mo Yulin has built an impressive career that bridges clinical practice and biomedical research. His professional journey began in June 2010 when he joined the Nanning Hospital of Traditional Chinese Medicine as a medium physician in the Internal Medicine and Physical Examination departments. Over six years in this role, he developed a strong clinical foundation and a growing interest in disease mechanisms and pharmacological interventions. After obtaining his Master’s degree, he returned to the same hospital in June 2019, this time focusing on a broader medical department, where he continues to practice medicine. During his tenure, Mo has maintained a dual focus on patient care and experimental research, allowing him to apply his laboratory insights to real-world medical challenges. He has collaborated with senior professionals and contributed to national-level research, while also mentoring younger colleagues in clinical routines and laboratory practices. His unique ability to translate bench-side findings to bedside interventions highlights his effectiveness as both a clinician and a researcher. With over a decade of continuous professional involvement in the medical field, Mo has shown commendable commitment, especially in the integration of traditional Chinese therapies with modern biomedical strategies.

Research Interest

Mo Yulin’s research interests lie primarily at the intersection of traditional Chinese medicine and modern pharmacological science, with a particular emphasis on bone-related disorders and oxidative stress mechanisms. He is especially passionate about understanding and treating glucocorticoid-induced osteoporosis (GIO) using molecular and cellular approaches. His master’s thesis explored the TXNIP-mediated mitochondrial oxidative phosphorylation pathway as a contributor to bone loss, representing a critical nexus of energy metabolism and bone pathology. Mo is also interested in the pharmacological potential of natural Chinese medicine, including monomer compounds and complex formulations, to treat chronic diseases such as osteoporosis, vascular diseases, and diabetes. Another area of interest includes modeling disease conditions in animals—he has mastered several techniques to establish experimental models, including ovariectomized rats and glucocorticoid-induced fracture models. Additionally, Mo is fascinated by the application of bioinformatics and network pharmacology to identify active compounds in traditional medicines and link them to molecular targets. His broader academic pursuit is to modernize traditional therapies by uncovering their mechanisms of action at the cellular and genetic level. By combining ancient medical wisdom with cutting-edge scientific techniques, he aims to contribute to integrative medicine and develop more effective, evidence-based therapeutic strategies.

Research Skills

Mo Yulin possesses a comprehensive skill set spanning molecular biology, pharmacological modeling, histology, and data analytics. He is highly proficient in conducting experiments involving animal models, particularly in the induction of osteoporosis and bone fractures in rodents. His technical skills include the extraction and culturing of bone marrow mesenchymal stem cells, human osteosarcoma cell lines, and various molecular biology assays like Western blotting, RT-qPCR, MTT assays, plasmid transfection, and siRNA interference. He is also skilled in bone histomorphometry, micro-CT analysis, and both decalcified paraffin and non-decalcified plastic embedding techniques. Mo is adept at performing immunohistochemistry and various types of staining for microscopic analysis. In addition to wet-lab skills, he is well-versed in statistical analysis and scientific computing using software such as SPSS, GraphPad Prism, and ImageJ. His ability to combine laboratory expertise with data interpretation and literature synthesis makes him a competent and independent researcher. Furthermore, he is capable of integrating traditional Chinese medicine theory with modern biochemical analysis, allowing for novel insights into drug mechanisms. These versatile research skills equip him to work on multidisciplinary projects in both academic and clinical research settings.

Awards and Honors

Throughout his academic and professional career, Mo Yulin has been recognized for his analytical acumen and research capability. During his undergraduate studies, he participated in the National College Students Mathematical Modeling Competitions, where he won the second prize in 2006 (Guangxi B group) and the third prize in 2007 (Guangxi group A). These early accomplishments reflected his strong foundation in analytical thinking and a keen interest in applying quantitative methods to solve biomedical problems. Later, his master’s thesis was selected for review by the Academic Degrees Committee of Guangdong Province, a sign of academic excellence. In addition, Mo has participated in several prestigious training programs and conferences, such as the Croucher Foundation’s summer course on Stem Cell Biology and Regenerative Medicine at the Chinese University of Hong Kong. He was also selected for training in Network Pharmacology Technology of Traditional Chinese Medicine and participated in the 9th International Academic Conference on Osteoporosis and Bone Mineral Salt Diseases, contributing to his professional growth and global exposure. These accolades, combined with his inclusion as a project participant in national-level funded research, highlight his growing stature as a serious and capable biomedical researcher.

Conclusion

In conclusion, Mo Yulin is a highly capable and dedicated researcher with a unique profile that bridges clinical medicine and pharmacological science, especially within the framework of Traditional Chinese Medicine. His academic achievements, research capabilities, and publication record affirm his suitability for a distinguished research career. He has already contributed valuable insights into the understanding and treatment of bone-related disorders and oxidative stress, demonstrated by peer-reviewed publications in high-impact journals and successful participation in national research projects. Mo’s well-rounded expertise, from cell culture and animal modeling to statistical data analysis and Chinese medicinal compound evaluation, gives him a holistic view of disease pathology and therapeutic mechanisms. Although a Ph.D. degree and more international collaborations could further enhance his research impact, his current contributions and potential for future work are substantial. Mo Yulin is not only a skilled physician but also a thoughtful researcher whose work continues to bridge gaps between traditional knowledge and modern science. Based on his achievements and potential, he stands out as a strong candidate for the Best Researcher Award.

Publications top Notes

  1. TXNIP contributes to bone loss via promoting the mitochondrial oxidative phosphorylation during glucocorticoid-induced osteoporosis
    Authors: Yulin Mo, Wenxiu Lai, Ying Zhong, Zhuoqing Hu, Meigui You, Minqun Du, Pan Wang, Xinyou Wu, Cailing Chen, Huanmin He, Zhimin Gao, Yaping Xu, Dongtao Wang, Liao Cui, Yajun Yang
    Year: 2021
    Journal: Life Sciences 266 (2021): 118938
  2. Tanshinol alleviates microcirculation disturbance and impaired bone formation by attenuating TXNIP signaling in GIO rats
    Authors: Wenxiu Lai, Yulin Mo, Dongtao Wang, Ying Zhong, Lujiao Lu, Jiajia Wang, Liao Cui, Yanzhi Liu, Yajun Yang
    Year: 2021
    Journal: Frontiers in Pharmacology, 12: 722175
  3. The mechanism of TXNIP-mediated oxidative stress in the disease
    Authors: Mo Yulin, Yang Yajun, Cui Liao
    Year: 2018